| 1 | Vlaicu, R., Niculescu, F.I., Rus, H.G ., and Cristea, A.: Immunofluorescent studies and quantitative determinations of immune related proteins in the human aortic fibrous plaque. Angeiologie ,35:229-236, 1983. |
| 2 | Cucuianu, M.P., Cristea, A., Roman,S., Rus, H.G ., Missits, I., and Pechet, L.: Comparative behavior of the components of factor VIII complex in acute myocardial infarction. Thomb Res. , 30: 487-497, 1983. |
| 3 | Niculescu F.I., Rus, H.G ., Cristea, A., and Vlaicu, R.: Localization of the terminal C5b-9 complement complex in the human aortic atherosclerotic wall. Immunol. Lett. , 10: 109-114, 1985. |
| 4 | Vlaicu R., Niculescu, F.I., Rus, H.G ., and Cristea, A.: Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis , 55: 35-55,1985. |
| 5 | Vlaicu, R., Niculescu, F.I., Rus, H.G. , and Cristea A.: Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaques. Atherosclerosis , 57: 163-177,1985. |
| 6 | Cucuianu, M.P., Rus, H.G ., Cristea, A., Niculescu, F.I., Bedeleanu, D., Porutiu, D., and Roman, S.: Clinical studies on plasma fibronectin and factor XIII with special reference to hyperlipoproteinemia. Clin. Chem. Acta. , 147: 273-281, 1985. |
| 7 | Rus, H.G ., Niculescu, F.I., Constantinescu, E., Cristea, A., and Vlaicu, R.: Immunoelectron microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis , 61: 35-42,1986. |
| 8 | Rus, H.G ., Niculescu, F., Nanulescu, M.N., Cristea, A., and Florescu, P.: Immunohistochemical detection of the terminal C5b-9 complement complex in children with glomerular diseases. Clin. Exp. Immunol. , 65: 66-72, 1986. |
| 9 | Cristea,A., Rus, H.G ., Niculescu, F., Bedeleanu, D., and Vlaicu, R.: Characterization of circulating immune complexes in heart diseases. Immunol. Lett. , 13: 45-49, 1986. |
| 10 | Niculescu, F., Rus, H.G. , and Vlaicu, R.: Immunohistochemical localization of C5b-9, S-protein, C3d, and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis , 65: 1-11,1987. |
| 11 | Niculescu, F., Hugo, F., Rus, H.G ., Vlaicu, R., and Bhakdi, S.: Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries. Clin. Exp. Immunol. , 69: 477-483, 1987. |
| 12 | Niculescu, F., Rus, H.G ., and Vlaicu, R.: Activation of the human terminal complement pathway in atherosclerosis. Clin. Immunol. Immunopathol. , 45: 147-155, 1987. |
| 13 | Rus, H.G ., Niculescu, F., and Vlaicu, R.: Presence of C5b-9 complement complex and S-protein in human myocardial areas with necrosis and sclerosis. Immunol Lett. , 16: 15-20, 1987. |
| 14 | Rus, H.G ., Niculescu, F., and Vlaicu, R.: The relationship between macrophages and C5b-9 complement complexes in human atherosclerosis. Clin. Immunol. Immunopathol. , 48: 307-316, 1988. |
| 15 | Rus, H.G ., Niculescu, F., and Vlaicu, R.: Colocalization of terminal C5b-9 complement complexes and macrophages in human atherosclerotic arterial walls. Immunol. Lett. , 19: 27-32, 1988. |
| 16 | Rus, H.G ., Niculescu, F., Porutiu, D., Ghiurca, V., and Vlaicu, R.: Cells carrying C5b-9 complement complexes in human atherosclerotic arterial wall. Immunol. Lett. , 20: 305-310, 1989. |
| 17 | Cucuianu, M.P., Rus, H.G ., Roman, S., Marcusiu, C., Spinu, C., Manasia, M., and Niculescu,F.: Tissue-type plaminogen activator and dilute blood clot lysis time in nephrotic patients. Thromb. Haemostas. , 61: 270-274, 1989. |
| 18 | Niculescu, F., Rus, H.G ., Porutiu, D., Ghiurca, V., and Vlaicu, R.: Immunoelectron microscopic localization of S-protein/vitronectin in human atherosclerotic wall. Atherosclerosis , 78: 197-203, 1989. |
| 19 | Cucuianu, M.P., Rus, H.G .: Factor XIII, fibronectin and clot lysis in hyperlipidemia. Thromb. Res. , 56: 501-502, 1989. |
| 20 | Niculescu, F., Rus, H.G ., and Vlaicu, R.: Decay-accelerating factor regulates complement mediated damage in human atherosclerotic wall. Immunol. Lett. , 26: 17-23, 1990. |
| 21 | Rus, H.G. , Niculescu, F., and Vlaicu, R.: Tumor necrosis factor a in human arterial atherosclerotic wall. Atherosclerosis , 89: 247-254, 1991. |
| 22 | Rus, H.G ., Kim, L., Niculescu, F., and Shin, M.L.: Regulation of C3 production in astrocytes by cytokines and Newcastle disease virus. J. Immunol. , 148: 928-933, 1992. |
| 23 | Niculescu, F., Rus, H.G ., Retegan, M., and Vlaicu, R.: Persistent complement activation on tumor cells in breast cancer. Am. J. Pathol. , 140: 1039-1043, 1992. |
| 24 | Niculescu, F., Lang, T., Rus, H.G ., Shin, H.S., and Shin, M.L.: Generation of diacylglycerol and ceramide during homologous complement activation. J. Immunol. , 150: 214-224, 1993. |
| 25 | Shirazi, Y., Rus, H.G ., Macklin, W.B., and Shin, M.L.: Enhanced degradation of messenger RNA encoding myelin proteins by terminal complement complexes. J. Immunol. , 150, 4581-4590, 1993. |
| 26 | Niculescu, F., Rus, H.G ., and Shin, M.L: Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal-complement complexes. J. Biol. Chem. , 269: 4417-4423, 1994. |
| 27 | Kim, Y-U., Rus, H.G. , Fisher, S.N., Pitha, P.M., and Shin, M.L.: Binding of a protein to an AU-rich domain of tumor necrosis factor a mRNA as a 35 kDa complex and its regulation in primary rat astrocytes. Biochem. J. 316: 455-460, 1996. |
| 28 | Rus, H.G ., Niculescu, F., and Shin, M.L.: Sublytic complement attack induces cell cycle in oligodendrocytes. J. Immunol. 156: 4892-4000, 1996. |
| 29 | Hänsch, G.M., Karnaoukhova, S., Chang, S.H., Rus, H ., Niculescu, F., Deppisch, R., Meissner, C., Ludwig, H., and Ritz, E.: Activation of human neutrophils after contact with cellulose-based haemodialysis membranes: intracellular calcium signalling in single cells. Nephrol. Dial. Transplant. 11: 2453-2460, 1996. |
| 30 | Niculescu, F., Rus, H ., Van Biesen, T., and Shin M.L.: Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J. Immunol. 158: 4405-4412, 1997. |
| 31 | Rus, H ., and Niculescu, F.: Inflammation, aspirin and the risk of cardiovascular diseas. N. Engl. J. Med . 337: 423,1997. |
| 32 | Rus, H. , Niculescu, F., Badea, T., and Shin, M.L.: Terminal complement complexes induce cell cycle entry in oligodendrocyte through mitogen activated protein kinase pathway. Immunopharmacol ., 38; 177-187, 1997. |
| 33 | Badea, T., Niculescu, F., Shin, M.L., and Rus, H . Molecular cloning and characterization of RGC 32, a novel gene induced by complement activation in oligodendrocytes. J. Biol. Chem. 273, 26977-26981, 1998. |
| 34 | Niculescu, F., Badea, T., and Rus, H .: Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells. Role of mitogen activated protein kinases and phosphatidylinositol 3-kinase. Atherosclerosis, 142, 47-56, 1999. |
| 35 | Niculescu, F., Soane, L., Badea, T., Shin, M.L., and Rus, H .: Tyrosine phosphorylation and activation of Janus kinase 1and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells. Immunopharmacology, 42: 187-193, 1999. |
| 36 | Rus, H . , and Niculescu, F.: Inflammatory response in unstable angina. Circulation, 100: e98, 1999. |
| 37 | Niculescu, F., and Rus, H .: Atherosclerosis and the immune system. Arch. Intern. Med.,159: 315,1999. |
| 38 | Niculescu, F., and Rus H . , Complement activation and atherosclerosis. Mol. Immunol. 36: 949-955, 1999 |
| 39 | Soane, L., Rus, H. , Niculescu, F., and Shin, M.L.: Inhibition of oligodendrocyte apoptosis by C5b-9 is associated with enhanced synthesis of Bcl-2 and mediated by inhibition of caspase-3 activation. J. Immunol. 163:6132-6138, 1999. |
| 40 | Dahiell, S, M, Rus H ,and Koski CL. Terminal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis. Glia 30: 187-198,2000. |
| 41 | Rus, H. , Niculescu, F., and Shin, M.L : Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol. Rev.180: 49-55, 2001. |
| 42 | Soane, L., Cho, H.J., Niculescu, F. Rus, H. , and Shin, M.L.: C5b-9 terminal complement complex protects oligodendrocyte from death by regulating BAD through PI-3 kinase/Akt pathway.J. Immunol. 167: 2305-2311, 2001. |
| 43 | Rus, H. and Niculescu, F., Role of complement system in central nervous systems disease . Immunol. Res. 24, 79-86 , 2001. |
| 44 | Niculescu, F and Rus H . Mechanisms of signal transduction by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res, 24, 191-199, 2001. |
| 45 | Badea, T., Niculescu, F., Soane, L., Fosbrink, M., Hila, S., Rus, V., Shin, M.L., and Rus, H . RGC 32, increases p34cdc2 activity and entry of aortic smooth muscle cells into S-phase. J. Biol. Chem. 277, 502-508, 2002. |
| 46 | Niculescu, F ., Nguyen, P., Niculescu, T., Rus, H., Rus, V. and Via, C.S. Signal transduction pathways activated in acute and chronic graft versus host disease (GVHD) in the parent-into-F1 mouse model (P->F1), Arthritis Rheum. 48, 1071-1079, 2003. |
| 47 | Weerth S., Rus, H. , Shin, M.L, and Raine, C.S.: Complement C5 in experimental autoimmune encephalomyelitis facilitates remyelination and prevents gliosis. Am. J. Pathol. 2003, 163, 1069-1080. |
| 48 | Rus, H. and Niculescu, F.,Association of complement inhibitors with connective tissue matrix in atherosclerotic lessions . Atheroscler. Thromb. Vasc. Biol. 2003, 23,1478. |
| 49 | Niculescu T., Weerth, S., Soane, L., Niculescu F., Rus, V., Raine, CS., Shin, M.L., and Rus H.G . Effects of membrane attack complex of complement on apoptosis in experimental autoimmune encephalomyelitis. Ann. N.Y. Acad Sci, 2003, 1010, 530-533. |
| 50 | Badea, T., Park, J-H., Soane, L., Niculescu, T., Niculescu, F., Rus, H., Shin, M.L. Sublytic terminal complement attack induces c-fos transcriptional activation in myotubes. J. Neuroimmunol. 2003, 142, 58-66. |
| 51 | Niculescu, F., Niculescu T., and Rus, H . C5b-9 complement complex assembly on apoptotic cells in human arterial wall with atherosclerosis. Exp. Mol. Pathol. 2004, 76, 17-23. |
| 52 | Niculescu T., Weerth, S., Niculescu F., Cudric, C.,Rus, V., Raine, CS., Shin, M.L.and Rus H. Effectof complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J. Immunol. 2004, 172, 5702-5707. |
| 53 | Niculescu, F, Rus, H. The role of complement activation in atherosclerosis. Immunol. Res. 2004, 30, 73-80. |
| 54 | Fosbrink, M, Niculescu, F, Rus, H. The role of C5b-9 terminal Complement Complex in activation of the cell cycle and transcription. Immunol. Res. 2005, 5, 37-46. |
| 55 | Fosbrink, M, Cudrici, C, Niculescu, F, Badea, C, David, S, Samsuddin, A, Shin, ML, Rus, H. Overexpression of RGC-32 in colon cancer and other tumors. Exp. Mol. Pathol. 2005, 78, 116-122. |
| 56 | Rus, H., Cudrici, C., Niculescu., F., C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: Dual role in neuroinflammation and neuroprotection. Ann. Med. 2005, 37, 97-104. |
| 57 | Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, Wulff H, Beeton C, Judge SI, Kerr DA, Knaus HG, Chandy KG, Calabresi PA. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A. 2005;102:11094-9. |
| 58 | Rus, H, Cudrici, C, Rus, H. The role of complement system in innate immunity. Immunol. Res. 2005, 33, 103-112. |
| 59 | Niculescu, F, T. Niculescu, Nguyen, P., Puliaev, R, Papadimitriou, J.C., Gaspari, A., Rus, H., and Via, C.S. Both apoptosis and complement membrane attack complex deposition are features of murine acute graft versus host disease. Exp. Mol. Pathol. 2005, 79, 136-145. |
| 60 |
Qiao M, Shapiro P, Fosbrink M, Rus H, Kumar R, Passaniti A. Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem. 2006, 281:7118-28. Jan 9; [Epub ahead of print]. |
| 60 | David S, Hila S, Fosbrink M, Rus H, Koski CL. JNK1 activation mediates C5b-9-induced P0 mRNA instability and P0 gene expression in Schwann cells. J Peripher Nerv Syst. 2006 :77-87. |
| 62 | Cornelia Cudrici, Florin Niculescu, Timothy Jansen, Ekaterina Zafranskaia, Matthew Fosbrink, Violeta Rus, Moon L. Shin, and Horea Rus. C5b-9 Terminal Complex Protects Oligodendrocytes from Apoptotic Cell Death by Inhibiting Caspase-8 Processing and Up-Regulating FLIP. J. Immunol. 2006; 176: 3173 – 3180. |
| 63 | Fosbrink M, Niculescu F, Rus V, Shin ML, Rus H. C5b-9 induced endothelial cell proliferation and migration is dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem. 2006 May 2; [Epub ahead of print] |
| 64 | Mullen KM, Rozycka M, Rus H, Hu L, Cudrici C, Zafranskaia E, Pennington MW, Johns DC, Judge SI, Calabresi P. Potassium channels K (v)1.3 and K(v)1.5 are expressed on blood-derived dendritic cells in the central nervous system. Ann Neurol. 2006 May 25; [Epub ahead of print] |
| 65 | Cudrici C, Niculescu T, Niculescu F , Shin ML, Rus H. Oligodendrocyte cell death in pathogenesis of multiple sclerosis. J Rehabil Res Dev. 2006, 43: 123-132. |
| 66 | Hoffman W, Cudrici C, Zafranskaia K, Rus H. Complement activation in diabetic ketoacidosis brains.Exp. Mol. Pathol. 2006, 80:283-288. |
| 67 | Fosbrink, M, Niculescu, F, Rus V, Shin ML, Rus, H. C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem. 2006, 281:19009-18. Epub 2006 May 2 |
| 68 | Rus, H, Cudrici, C, David, S., Niculescu, F., The complement system in central nervous system diseases. Autoimmunity, 2006, 39, 395-402. |
| 69 | Rus, H, Cudrici, C, Niculescu, F, Shin, M.L. Complement system in autoimmune demyelination: Dual role in neuroinflammation and neuroprotection. J. Neuroimmunol. 2006, 180, 9-16. |
| 70 | Hoffman W, Casanova, MF, Cudrici C, Zafranskaia K, Venugopalan R, Nag, S, Oglesbee MG Rus H. Neuroinflammatory response of choroid plexus epithelium in fatal diabetic ketoacidosis. Exp. Mol. Pathol. 2007, 83:65-72, Epub Jan 30. |
| 71 | Cudrici, C, Ito, T, Zafranskaia, E, Niculescu, F, Mullen, K, M, Vlaicu, S, Judge, S, Calabresi P. A, Rus, H. Dendritic cells are abundant in non-lesional gray matter in multiple sclerosis. Exp. Mol. Pathol. 2007, 83, 198-206. |
| 72 | Oh S, Cudrici, C, Ito, T, Rus, H. B-cells and humoral immunity in multiple sclerosis. Implications for therapy. Immunol Res. 2008, 40: 224-234. |
| 73 | Vlaicu SI, Cudrici C, Ito T, Fosbrink M, Tegla CA, Rus V, Mircea PA, Rus H. Role of response gene to complement 32 in diseases. Arch Immunol Ther Exp . 2008, 56, 115-121. |
| 74 | Cudrici, C, T. Ito, E. Zafranskaia, S. Weerth, H.H. Chen, A. Gherman, Niculescu, F, K. Soloviova, C. Tegla, V. Rus, C. S. Raine, H. Rus. Complement C5 regulates expression of Insulin-like growth factors binding proteins in chronic experimental allergic encephalomyelitis. J. Neuroimmunol. , 2008 203, 94-103, Epub August 7. |
| 75 | Fosbrink, M, Cudrici, C, Tegla, C. A., Soloviova, K, Ito, T, Vlaicu, S, Rus, V, Niculescu, F, Rus, H. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells, Exp. Mol. Pathol. 2009, 86:87-94 |
| 76 | Huang WY, Li ZG, Rus H, Wang X, Jose PA, Chen SY. RGC-32 Mediates Transforming Growth Factor-{beta}-induced Epithelial-Mesenchymal Transition in Human Renal Proximal Tubular Cells. J Biol Chem. 2009, 284: 9426-32. |
| 77 | Nguyen, V, Cudrici, C, Zernetkina, V, Niculescu, F, Rus, H, Drachenberg, C, Rus, V. TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects. Clin Immunol. 132, 32-42. |
| 78 | Tegla, CA, Cudrici, C, Rus, V, Ito, T, Vlaicu, S, Singh A, Rus H. Neuroprotective effects of the complement terminal pathway during demyelination: Implications for oligodendrocyte survival. J. Neuroimmunol. 2009, 213, 3-11. |
| 79 | Vlaicu, S., Tegla, TA, Cudrici, C, Fosbrink, M, Nguyen, V., Azimzadeh, P, Rus, V., Chen, H, Mircea, P, Rus, H. Epigenetic modifications induced by RGC-32 in colon cancer. Exp. Mol. Pathol. 2010, 88:67-76. |
| 80 | Ford C, Johnson K, Kachuck N, Linsey WJ, Lisak, R, Luzzio C, Myers, L, Panitch, H, Preiningerova, J, Pruitt, A, Rose, J, Rus, H., Wolinsky, J. Continuous long-term immunomodulatory therapy in relapsing-remitting multiple sclerosis: results from 15-year analysis of US prospective open-label study of glatiramer acetate. Mult Scler. 2010, 16, 342-350 |
| 81 | Cynthia A. DeBoy, Horea Rus, Cosmin Tegla, Cornelia Cudrici, Melina V. Jones, Carlos A. Pardo, Donald Small, Katharine A. Whartenby and Peter A. Calabresi. FLT-3 expression and function on microglia in multiple sclerosis. Exp. Mol. Pathol. 2010, 89:109-116. |
| 82 | Tegla CA, Cudrici C, Rozycka M, Soloviova K, Ito T, Singh AK, Khan A, Azimzadeh P, Andrian-Albescu M, Khan A, Niculescu F, Rus V, Judge SI, Rus H. C5b-9-activated, K(v)1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation. Exp Mol Pathol. 2011, 91:335-345. |
| 83 | Tegla CA, Cudrici C, Patel S, Trippe R 3rd, Rus V, Niculescu F, Rus H. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. 2011, 51:45-60. |
| 84 | Nguyen V, Luzina I, Rus H, Tegla C, Chen C, Rus V. IL-21 promotes Lupus-like disease in chronic graft-versus-host disease through both CD4 T-cells and B-cells intrinsic mechanism. J. Immunol, 2012, 189, 1081-1093. |
| 85 | Tegla CA, Cudrici CD, Azimzadeh P, Singh AK, Trippe R 3rd, Khan A, Chen H, Andrian-Albescu M, Royal W 3rd, Bever C, Rus V, Rus H. Dual role of Response gene to complement-32 in multiple sclerosis. Exp Mol Pathol. 2013, 94(1):17-28.E-Pub Sep 18. |
| 86 | Vlaicu SI, Tegla CA, Cudrici CD, Danoff J, Madani H, Sugarman A, Niculescu F, Mircea PA, Rus V, Rus H. Role of C5b-9 complement complex and Response gene to complement-32 in cancer. Immunol Res. 2013, 56:109-21 E-Pub Dec 18 |
| 87 | Tegla CA, Azimzadeh P, Andrian-Albescu M, Martin A, Cudrici CD, Trippe R 3rd, Sugarman A, Chen H, Boodhoo D, Vlaicu SI, Royal W 3rd, Bever C, Rus V, Rus H. SIRT1 is decreased during relapses in patients with multiple sclerosis. Exp Mol Pathol. 2014, 96. 139–148 |
| 88 | Martin A, Tegla CA, Cudrici CD, Kruszewski AM, Azimzadeh P, Boodhoo D, Mekala AP, Rus V, Rus H. Role of SIRT1 in autoimmune demyelination and neurodegeneration. Immunol Res. 2015, 61:187-97. |
| 89 | Tegla CA, Cudrici CD, Nguyen V, Danoff J, Kruszewski AM, Boodhoo D, Mekala AP, Vlaicu SI, Chen C, Rus V, Badea TC, Rus H. RGC-32 is a novel regulator of the T-lymphocyte cell cycle. Exp Mol Pathol. 2015, 98 :328-37. |
| 90 | Demicheva E, Cui YF, Bardwell P, Barghorn S, Kron M, Meyer AH, Schmidt M, Gerlach B, Leddy M, Barlow E, O'Connor E, Choi CH, Huang L, Veldman GM, Rus H, Shabanzadeh AP, Tassew NG, Monnier PP, Müller T, Calabresi PA, Schoemaker H, Mueller BK. Targeting Repulsive Guidance Molecule A to Promote Regeneration and Neuroprotection in Multiple Sclerosis. Cell Rep. 2015, 10, 1887–1898. |
| 91 | Kruszewski AM, Rao G, Tatomir A, Hewes D, Tegla CA, Cudrici CD, Nguyen V, Royal W 3rd, Bever CT Jr, Rus V, Rus H. RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. Exp Mol Pathol. 2015, 99: 498-505. |
| 92 | Vlaicu SI, Tatomir A, Rus V, Mekala AP, Mircea PA, Niculescu F, Rus H. The role of complement activation in atherogenesis: the first 40 years. Immunol Res. 2016, 64: 1-13. |
| 93 | Vlaicu SI, Tatomir A, Boodhoo D, Vesa S, Mircea PA, Rus H. The role of complement system in adipose tissue-related inflammation. Immunol Res. 2016 64 :653-64. |
| 94 | Nguyen V, Rus H, Chen C, Rus V. CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the Parent→F1 Graft-versus-Host Disease Model. J Immunol. 2016 15; 196:1529-40. |
| 95 | Vlaicu SI, Tatomir A, Boodhoo D, Ito T, Fosbrink M, Cudrici C, Mekala AP, Ciriello J, Crişan D, Boţan E, Rus V, Rus H. RGC-32 is expressed in the human atherosclerotic arterial wall: Role in C5b-9-induced cell proliferation and migration. Exp Mol Pathol. 2016, 101:221-230 |
| 96 | Vlaicu SI, Tatomir A, Boodhoo D, Ito T, Fosbrink M, Cudrici C, Mekala AP, Ciriello J, Crişan D, Boţan E, Rus V, Rus H. RGC-32 is expressed in the human atherosclerotic arterial wall: Role in C5b-9-induced cell proliferation and migration. Exp Mol Pathol. 2016, 101:221-230. |
| 97 | Hewes D, Tatomir A, Kruszewski AM, Rao G, Tegla CA, Ciriello J, Nguyen V, Royal W 3rd, Bever C, Rus V, Rus H. SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis. Exp. Mol. Pathol. 2017, 102,191-197. |
| 98 | Rus V, Nguyen V, Tatomir A, Lees JR, Mekala AP, Boodhoo D, Tegla CA, Luzina IG, Antony PA, Cudrici CD, Badea TC, Rus HG. RGC-32 Promotes Th17 Cell Differentiation and Enhances Experimental Autoimmune Encephalomyelitis. J. Immunol. 2017, 198:3869-3877. |
| 99 | Hoffman WH, Artlett CM, Boodhoo D, Gilliland MGF, Ortiz L, Mulder D, Tjan DHT, Martin A, Tatomir A, Rus H. Markers of immune-mediated inflammation in the brains of young adults and adolescents with type 1 diabetes and fatal diabetic ketoacidosis. Is there a difference?. Exp Mol Pathol. 2017, 102:505-514, |
| 100 | Tatomir A, Talpos-Caia, A, Anselmo, F, Kruszewski AM, Boodhoo D, Rus V, Rus H, The role of complement system as a biomarker of disease activity and response to treatment in multiple sclerosis. Immunol Res. 2017 Nov 8. doi: 10.1007/s12026-017-8961-8. [Epub ahead of print]. |
RusLab Home Page
subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link
subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link
subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link
subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link
subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link
subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link